BioCentury
ARTICLE | Company News

Epigenomics, Cathay Fortune deal

April 28, 2017 5:56 PM UTC

Cathay's Blitz F16-83 GmbH subsidiary will acquire molecular diagnostics company Epigenomics for €7.52 per share, or about €171 million ($185.6 million) in cash. The price is a 52% premium on Epigenomics' closing price of €4.95 on April 25.

Blitz F16-83 will change its name to Summit Hero Holding GmbH. Epigenomics' partner and largest shareholder BioChain Institute Inc. (Newark, Calif.) will own an indirect stake in Summit...

BCIQ Target Profiles

Septin 9 (SEPT9)